Analysis weighs benefits, adverse effects of RLS drugs

05/12/2008 | Forbes

A meta-analysis of 14 trials involving four nonergot dopamine agonists -- first-line treatments for restless legs syndrome -- found that the drug ropinerole appeared to cause the "most profound side effects," leading patients to stop therapy. The American College of Neurology will release guidelines on the use of NEDA medicines by the end of the year, an expert said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ